IPG7236

DRUG2 trials

Sponsors

Nanjing Immunophage Biotech Co., Ltd

Conditions

Advanced Solid TumorPharmacokineticsSafety IssuesTolerability

Phase 1

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

CompletedNCT05142592

Nanjing Immunophage Biotech Co., LtdPharmacokinetics, Safety Issues, Tolerability

Start: 2021-11-15End: 2026-03-05Updated: 2026-07-08

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

RecruitingNCT07508761

Nanjing Immunophage Biotech Co., LtdAdvanced Solid Tumor

Start: 2026-06-16End: 2029-07-30Target: 52Updated: 2026-06-29